Many new developments in the treatment of vasculitis

Publisher’s note: This is an automatically generated transcription, which has been slightly modified for more clarity. Please inform [email protected] if there are concerns about the accuracy of the transcription.

Well, we are very delighted that we have a multiple development in the study of vasculitic treatment, and all this because we meet as a community of different researchers and gather every effort, so now we have seen Course of the last five, 10 years, and a little more, that we have a group of investigators who, although it is a rare disease, we are able to look at this in a more inclusive question, and It helped us have a lot of patients in a single study. Thus, for example, you know, just from the meeting of the American College of Rheumatology that we have just done in November, we have had several studies.

They were presented and some of them took the plenary session. We have learned that the abacap has not reduced the risk of relapse in the vasculitis associated with the ANCA. There has been a lot of effort in recent years to watch and study EGPA, eosinophilic granulomatosis with polyangiitis, and mantra test was presented at the ACR meeting, which showed That benralizumab is not lower than the milestone in the manifestation of the airways and without air of the airways and without air of the demonstration of the airways and the airways in EGPA. We were also a major study that was also presented, it was a test selected by GCA, and it was an attempt in arteritis of giant cells, and which showed that upadacitinib in a dose 15 milligrams was more effective in reducing glucocorticoids in GCA.

And we continued to see several post-hoc studies after the Advocate test which was presented a few years ago, and now we have seen a multiple analysis of post-hoc analysis which shows thatVacopan is effective in other that non -renal participation, general symptoms, involvement of the nervous system, skin, eyes and other involvement. So, I can continue and continue, but it is the highest point of major studies that have been presented to the American College of Rheumatology recently.